Epstein-Barr virus nuclear antigen EBNA3A modulates IRF3-dependent IFNβ expression.

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• Epstein-Barr virus (EBV) infects most adults and is linked to cancers.
• EBV evades host antiviral immunity, particularly type I interferon (IFN I) responses.
• Mechanisms by which EBV genes inhibit IFN I induction are not fully understood.

Purpose of the Study:

• To investigate how EBV nuclear antigen 3A (EBNA3A) inhibits IFNβ induction.
• To identify EBNA3A's interaction partners involved in IFNβ regulation.

Main Methods:

• Proximity biotinylation to identify EBNA3A binding partners.
• Co-immunoprecipitation assays to confirm protein interactions.
• Analysis of transcription factor binding to the IFNβ promoter.

Main Results:

• EBNA3A binds to the histone acetyltransferase P300, a component of the IFNβ transcriptional complex.
• EBNA3A also interacts with interferon regulatory factor 3 (IRF3) in the nucleus.
• These interactions, mediated by EBNA3A's N-terminal domain, are proposed to hinder IRF3 binding to the IFNβ promoter.

Conclusions:

• EBNA3A inhibits IFNβ induction by interfering with the IFNβ transcriptional complex.
• This mechanism represents a novel immune evasion strategy employed by EBV.
• Targeting EBNA3A could disrupt EBV's ability to suppress host antiviral immunity.